{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:53Z","timestamp":1789014533427,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02421-z","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:16:07Z","timestamp":1781270167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Consistency of response to rimegepant for the acute treatment of migraine among real-world users \u2013 findings from the prospective observational CONFIDENCE study"],"prefix":"10.1186","volume":"27","author":[{"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Urani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Lambru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd J.","family":"Schwedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina M.","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Hygge","family":"Blakeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"6","key":"2421_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11916-004-0064-2","volume":"8","author":"DW Dodick","year":"2004","unstructured":"Dodick DW, Lipton RB, Ferrari MD, Goadsby PJ, McCrory D, Cutrer FM, Williams P (2004) Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR project. Curr Sci Inc 8(6):435\u2013442. https:\/\/doi.org\/10.1007\/s11916-004-0064-2","journal-title":"Curr Sci Inc"},{"issue":"6","key":"2421_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","volume":"39","author":"H-C Diener","year":"2019","unstructured":"Diener H-C, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang S-J, Mandrekar J (2019) Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Fourth Ed Cephalalgia 39(6):687\u2013710. https:\/\/doi.org\/10.1177\/0333102419828967","journal-title":"Fourth Ed Cephalalgia"},{"key":"2421_CR3","doi-asserted-by":"publisher","unstructured":"Smelt AFH, Louter MA, Kies DA, Blom JW, Terwindt GM, van der Heijden GJMG, De Gucht V, Ferrari MD, Assendelft WJJ (2014) What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi study. PLoS One 9(6):e98933. https:\/\/doi.org\/10.1371\/journal.pone.0098933","DOI":"10.1371\/journal.pone.0098933"},{"issue":"5","key":"2421_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1524-4733.2008.00320.x","volume":"11","author":"ML Martin","year":"2008","unstructured":"Martin ML, Patrick DL, Bushnell DM, Gandra SR, Gilchrist K (2008) Further validation of an individualized migraine treatment satisfaction measure. Value Health 11(5):904\u2013912. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00320.x","journal-title":"Value Health"},{"issue":"7","key":"2421_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1468-2982.2008.01786.x","volume":"29","author":"R Lipton","year":"2009","unstructured":"Lipton R, Kolodner K, Bigal M, Valade D, L\u00e1inez M, Pascual J, Gendolla A, Bussone G, Islam N, Albert K, Parsons B (2009) Validity and reliability of the migraine-treatment optimization questionnaire. Cephalalgia 29(7):751\u2013759. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01786.x","journal-title":"Cephalalgia"},{"issue":"Suppl s1","key":"2421_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1526-4610.2002.0420s1003.x","volume":"42","author":"RB Lipton","year":"2002","unstructured":"Lipton RB, Hamelsky SW, Dayno JM (2002) What do patients with migraine want from acute migraine treatment? Headache 42(Suppl s1):3\u20139. https:\/\/doi.org\/10.1046\/j.1526-4610.2002.0420s1003.x","journal-title":"Headache"},{"issue":"4","key":"2421_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1526-4610.2006.00403.x","volume":"46","author":"SG Kilminster","year":"2006","unstructured":"Kilminster SG, Dowson AJ, Tepper SJ, Baos V, Baudet F, D\u2019Amico D (2006) Reliability, validity, and clinical utility of the migraine-ACT questionnaire. Headache 46(4):553\u2013562. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00403.x","journal-title":"Headache"},{"issue":"3","key":"2421_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0333102421989247","volume":"41","author":"HC Diener","year":"2021","unstructured":"Diener HC, Ashina M, Durand-Zaleski I, Kurth T, Lant\u00e9ri-Minet M, Lipton RB, Ollendorf DA, Pozo-Rosich P, Tassorelli C, Terwindt G (2021) Health technology assessment for the acute and preventive treatment of migraine: a position statement of the International Headache Society. Cephalalgia 41(3):279\u2013293. https:\/\/doi.org\/10.1177\/0333102421989247","journal-title":"Cephalalgia"},{"issue":"2","key":"2421_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/head.14067","volume":"61","author":"CR Houts","year":"2021","unstructured":"Houts CR, McGinley JS, Nishida TK, Buse DC, Wirth RJ, Dodick DW, Goadsby PJ, Lipton RB (2021) Systematic review of outcomes and endpoints in acute migraine clinical trials. Headache 61(2):263\u2013275. https:\/\/doi.org\/10.1111\/head.14067","journal-title":"Headache"},{"issue":"3","key":"2421_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40263-023-00988-8","volume":"37","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023) Rimegepant: a review in the acute treatment and preventive treatment of migraine. CNS Drugs 37(3):255\u2013265. https:\/\/doi.org\/10.1007\/s40263-023-00988-8","journal-title":"CNS Drugs"},{"issue":"11","key":"2421_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/14737175.2024.2401558","volume":"24","author":"WD Wells-Gatnik","year":"2024","unstructured":"Wells-Gatnik WD, Pellesi L, Martelletti P (2024) Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Expert Rev Neurotherapeutics 24(11):1107\u20131117. https:\/\/doi.org\/10.1080\/14737175.2024.2401558","journal-title":"Expert Rev Neurotherapeutics"},{"issue":"5","key":"2421_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17581869.2025.2494494","volume":"15","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Jedie B, Barhum F, Al-Abdullah S, Martelletti P, Xiao Z (2025) Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manag 15(5):279\u2013284. https:\/\/doi.org\/10.1080\/17581869.2025.2494494","journal-title":"Pain Manag"},{"key":"2421_CR13","unstructured":"European Medicines Agency (2022) Vydura (rimegepant) summary of production information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vydura-epar-product-information_en.pdf. 9 March 2026"},{"key":"2421_CR14","unstructured":"US Food and Drug Administration (2020) Nurtec ODT (rimegepant) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212728s026lbl.pdf. 9 March 2026"},{"key":"2421_CR15","unstructured":"Migraine Buddy (2024) Migraine Buddy app. 9 March 2026 https:\/\/migrainebuddy.com\/"},{"issue":"12","key":"2421_CR16","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1111\/ene.15037","volume":"28","author":"PJ Goadsby","year":"2021","unstructured":"Goadsby PJ, Constantin L, Ebel-Bitoun C, Igracki Turudic I, Hitier S, Amand-Bourdon C, Stewart A (2021) Multinational descriptive analysis of the real-world burden of headache using the migraine Buddy application. Euro J Neurol 28(12):4184\u20134193. https:\/\/doi.org\/10.1111\/ene.15037","journal-title":"Euro J Neurol"},{"issue":"8","key":"2421_CR17","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/head.15016","volume":"65","author":"A Ezzati","year":"2025","unstructured":"Ezzati A, Fanning KM, Teichrow D, Urani A, Cadiou F, Lipton RB (2025) Headache assessment via digital platform in United States: baseline study characteristics, diagnosis, and treatment patterns. Headache 65(8):1428\u20131438. https:\/\/doi.org\/10.1111\/head.15016","journal-title":"Headache"},{"key":"2421_CR18","doi-asserted-by":"publisher","unstructured":"Ezzati A, Fanning K, Urani A, Cadiou F, Lipton R (2024) A comparison of Headache Assessment via Digital platform in United States (HeAD-US) and American migraine prevalence and Prevention (AMPP) studies: baseline demographics and headache characteristics (P1-12.002). Neurology 102(7_supplement_1):6686. https:\/\/doi.org\/10.1212\/WNL.0000000000206629","DOI":"10.1212\/WNL.0000000000206629"},{"issue":"10","key":"2421_CR19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/head.14839","volume":"64","author":"AR Shewale","year":"2024","unstructured":"Shewale AR, Poh W, Reed ML, Liu J, Cadiou F, Ezzati A, Burslem K, Manthena S, Lipton RB (2024) Ubrogepant users\u2019 real-world experience: patients on ubrogepant, characteristics and outcomes (UNIVERSE) study. Headache 64(10):1244\u20131252. https:\/\/doi.org\/10.1111\/head.14839","journal-title":"Headache"},{"issue":"1","key":"2421_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17581869.2025.2585269","volume":"16","author":"RB Lipton","year":"2026","unstructured":"Lipton RB, Bodhani A, Gao X, Duan M, Wilson L, Cadiou F, Gandhi P, Jariwala-Parikh K (2026) Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant. Pain Manag 16(1):39\u201348. https:\/\/doi.org\/10.1080\/17581869.2025.2585269","journal-title":"Pain Manag"},{"issue":"1","key":"2421_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-023-01622-0","volume":"24","author":"A Manack Adams","year":"2023","unstructured":"Manack Adams A, Hutchinson S, Engstrom E, Ayasse ND, Serrano D, Davis L, Sommer K, Contreras-De Lama J, Lipton RB (2023) Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE study. J Headache Pain 24(1):102. https:\/\/doi.org\/10.1186\/s10194-023-01622-0","journal-title":"J Headache Pain"},{"issue":"1","key":"2421_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40120-023-00556-8","volume":"13","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Contreras-De Lama J, Serrano D, Engstrom E, Ayasse ND, Poh W, Cadiou F, Manack Adams A (2024) Real-world use of ubrogepant as acute treatment for migraine with an anti-calcitonin gene-related peptide monoclonal antibody: results from COURAGE. Neurol Ther 13(1):69\u201383. https:\/\/doi.org\/10.1007\/s40120-023-00556-8","journal-title":"Neurol Ther"},{"issue":"2","key":"2421_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40120-018-0113-0","volume":"7","author":"P Vo","year":"2018","unstructured":"Vo P, Paris N, Bilitou A, Valena T, Fang J, Naujoks C, Cameron A, de Reydet de Vulpillieres F, Cadiou F (2018) Burden of migraine in europe using self-reported digital diary data from the migraine Buddy\u00a9 application. Neurol Ther 7(2):321\u2013332. https:\/\/doi.org\/10.1007\/s40120-018-0113-0","journal-title":"Neurol Ther"},{"key":"2421_CR24","doi-asserted-by":"publisher","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56(suppl_1):S20\u2013S28. https:\/\/doi.org\/10.1212\/WNL.56.suppl_1.S20","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"issue":"7","key":"2421_CR25","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/wnl.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84(7):688\u2013695. https:\/\/doi.org\/10.1212\/wnl.0000000000001256","journal-title":"Neurology"},{"key":"2421_CR26","doi-asserted-by":"publisher","unstructured":"Atkinson MJ, Kumar R, Cappelleri JC, Hass SL (2005) Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 8(Suppl, 1):S9\u2013s24. https:\/\/doi.org\/10.1111\/j.1524-4733.2005.00066.x","DOI":"10.1111\/j.1524-4733.2005.00066.x"},{"issue":"1","key":"2421_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2(1):12. https:\/\/doi.org\/10.1186\/1477-7525-2-12","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2421_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Ulud\u00fcz D, Versijpt J, Ducros A, Gil-Gouveia R, Katsarava Z, Martelletti P, Ornello R, Raffaelli B, Boucherie DM, Pozo-Rosich P, Sanchez-Del-Rio M, Sinclair A, Maassen van den Brink A, Reuter U (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23(1):133. https:\/\/doi.org\/10.1186\/s10194-022-01502-z","journal-title":"J Headache Pain"},{"issue":"8","key":"2421_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","volume":"22","author":"MD Ferrari","year":"2002","unstructured":"Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22(8):633\u2013658. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00404.x","journal-title":"Cephalalgia"},{"key":"2421_CR30","doi-asserted-by":"publisher","unstructured":"Dahl\u00f6f CGH, Lipton RB, McCarroll KA, Kramer MS, Lines CR, Ferrari MD (2000) Within-patient consistency of response of rizatriptan for treating migraine. Neurology 55(10):1511\u20131516. https:\/\/doi.org\/10.1212\/WNL.55.10.1511","DOI":"10.1212\/WNL.55.10.1511"},{"issue":"3","key":"2421_CR31","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40120-022-00369-1","volume":"11","author":"T Yu","year":"2022","unstructured":"Yu T, He L, Yang X, Zhou J, Luo G, Wang H, Zhao H, Hu Q, Ji F, Yu S (2022) Efficacy and safety of lasmiditan as a novel acute treatment in Chinese patients with migraine: a subpopulation analysis of the randomized controlled phase 3 CENTURION trial. Neurol Ther 11(3):1269\u20131283. https:\/\/doi.org\/10.1007\/s40120-022-00369-1","journal-title":"Neurol Ther"},{"issue":"3","key":"2421_CR32","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise SR, Bragg S, Doty EG, Dowsett SA, Lin Q, Krege JH (2021) Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia 41(3):294\u2013304. https:\/\/doi.org\/10.1177\/0333102421989232","journal-title":"Cephalalgia"},{"issue":"8","key":"2421_CR33","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1468-2982.2008.01806.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Dodick DW, Adelman JU, Kaniecki RG, Lener SE, White JD, Nelsen AC (2009) Consistency of response to sumatriptan\/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia 29(8):826\u2013836. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01806.x","journal-title":"Cephalalgia"},{"key":"2421_CR34","doi-asserted-by":"publisher","unstructured":"Abraham L, Brown J, Blakeman KH, Feng D, Jackson J, Whitton W, Barlow S, Hancock L (2025) Treatment outcomes in people with migraine receiving rimegepant or triptans: a descriptive analysis from a real-world survey (P1-12.008). Neurology 104(7_Supplement_1):2622. https:\/\/doi.org\/10.1212\/WNL.0000000000210468","DOI":"10.1212\/WNL.0000000000210468"},{"issue":"12","key":"2421_CR35","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/brainsci14121169","volume":"14","author":"EV Dermitzakis","year":"2024","unstructured":"Dermitzakis EV, Rikos D, Vikelis M, Xiromerisiou G, Zisopoulou S, Rallis D, Soldatos P, Vlachos GS, Vasiliadis GG, Argyriou AA (2024) Real-world open-label experience with rimegepant for the acute treatment of migraine attacks: a multicenter pilot study. Brain Sci 14(12):1169. https:\/\/doi.org\/10.3390\/brainsci14121169","journal-title":"Brain Sci"},{"issue":"4","key":"2421_CR36","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/head.14062","volume":"61","author":"CC Chiang","year":"2021","unstructured":"Chiang CC, Arca KN, Dunn RB, Girardo ME, Quillen JK, Dodick DW, Starling AJ (2021) Real-world efficacy, tolerability, and safety of ubrogepant. Headache 61(4):620\u2013627. https:\/\/doi.org\/10.1111\/head.14062","journal-title":"Headache"},{"key":"2421_CR37","doi-asserted-by":"publisher","unstructured":"Lipton RB, Dodick DW, Goadsby PJ, Burstein R, Adams AM, Lai J, Yu SY, Finnegan M, Kuang AW, Trugman JM (2022) Efficacy of ubrogepant in the acute treatment of migraine with mild pain vs moderate or severe pain. Neurology 99(17):e1905\u2013e1915. https:\/\/doi.org\/10.1212\/WNL.0000000000201031","DOI":"10.1212\/WNL.0000000000201031"},{"issue":"1","key":"2421_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","volume":"14","author":"L Dong","year":"2025","unstructured":"Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D (2025) The global burden of migraine: a 30-year trend review and future projections by age, sex, country, and region. Pain Ther 14(1):297\u2013315. https:\/\/doi.org\/10.1007\/s40122-024-00690-7","journal-title":"Pain Ther"},{"issue":"10200","key":"2421_CR39","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s0140-6736(19)31606-x","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737\u2013745. https:\/\/doi.org\/10.1016\/s0140-6736(19)31606-x","journal-title":"Lancet"},{"issue":"2","key":"2421_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ (2019) Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine. N Engl J Med 381(2):142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"key":"2421_CR41","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/jpr.S453806","volume":"17","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Thiry A, Morris BA, Croop R (2024) Efficacy and safety of rimegepant 75 mg oral tablet, a CGRP receptor antagonist, for the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. JPain Res 17:2431\u20132441. https:\/\/doi.org\/10.2147\/jpr.S453806","journal-title":"JPR"},{"issue":"1","key":"2421_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-024-01731-4","volume":"25","author":"S Yu","year":"2024","unstructured":"Yu S, Guo A, Wang Z, Liu J, Tan G, Yang Q, Zhang M, Yibulaiyin H, Chen H, Zhang Y, Croop R, Sun Y, Liu Y, Zhao Q, Lu Z (2024) Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial. J Headache Pain 25(1):57. https:\/\/doi.org\/10.1186\/s10194-024-01731-4","journal-title":"J Headache Pain"},{"issue":"10","key":"2421_CR43","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1111\/head.14994","volume":"65","author":"K Ikeda","year":"2025","unstructured":"Ikeda K, Matsumori Y, Kudo M, Ishikawa T, Hoshino Y, Yoshimatsu H, Thiry A, Arakawa A, Croop R, Fullerton T, Sakai F, Takeshima T (2025) Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: a dose-ranging, double-blind, randomized controlled trial. Headache 65(10):1811\u20131820. https:\/\/doi.org\/10.1111\/head.14994","journal-title":"Headache"},{"issue":"2","key":"2421_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34(2):114\u2013125. https:\/\/doi.org\/10.1177\/0333102413500727","journal-title":"Cephalalgia"},{"issue":"6","key":"2421_CR45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/00325481.2025.2518043","volume":"137","author":"SJ Tepper","year":"2025","unstructured":"Tepper SJ, Pavlovic JM, Yu S, Lipton RB, Pixton G, Zou Y, Fountaine RJ, Semel D (2025) Efficacy and safety of rimegepant 75 mg for acute treatment of migraine: a pooled analysis of four randomized, placebo-controlled trials. Postgrad Med 137(6):503\u2013513. https:\/\/doi.org\/10.1080\/00325481.2025.2518043","journal-title":"Postgrad Med"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02421-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02421-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02421-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:23:04Z","timestamp":1786015384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02421-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02421-z","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol and all relevant documents were prospectively approved by an Institutional Review Board (Advarra, Pro00079359). The study was conducted in accordance with all legal and regulatory requirements, and according to good practice guidelines in relation to pharmacoepidemiologic research. All participants provided informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RBL: Editorial board of Neurology and senior advisor to Headache (not paid); research support: NIH and FDA; support from the National Headache Foundation; research grants, consultant, advisory board member or honoraria: Aeon, Allergan\/AbbVie, Amgen, Axsome, Dr Reddy\u2019s Laboratories, Eli Lilly, GSK, Ipsen, Lundbeck, Pfizer, Merck, Teva, Vedanta; royalties from Informa and Wolff\u2019s Headache (8th edition, Oxford University Press, 2009); stock options in Biohaven Pharmaceuticals, CoolTech, Manistee, and NuVieBio. AU: Employee of Aptar Digital Health, which was a paid consultant to Pfizer for the conduct of this study. GL: Consulting fees: AbbVie, Dr Reddy\u2019s Laboratories, Eli Lilly, Lundbeck, Pfizer, and Teva. PJG: Consulting fees: Aeon, AbbVie, CoolTech, Dr Reddy\u2019s Laboratories, Eli Lilly, Epalex, Ipsen, Kallyope, Linpharma, Lundbeck, Orion Pharma, Pfizer, PureTech Health, Satsuma, Seaport Therapeutics, Shiratronics, Teva; personal fees for advice: Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Psychometric; fees for educational materials: CME Outfitters and WebMD; publishing royalties or fees: Massachusetts Medical Society, Oxford University Press, UptoDate, and Wolters Kluwer. PP-R: In the last 3\u2009years, consultant and speaker: AbbVie, Almirall, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Otsuka Pharmaceuticals, Pfizer, Teva; research grants to her research group: AbbVie, AGAUR, EraNet Neuron, FEDER RIS3CAT, Instituto Investigaci\u00f3n Carlos III, MICINN, Novartis, Teva; funding for clinical trials: AbbVie, Amgen, Eli Lilly, Lundbeck, Merz, Pfizer, Teva; associate editor for Cephalalgia, NS Neurologia; member of the Clinical Trials Guidelines Committee and Scientific Committee of the International Headache Society; edited Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society; founder of\n                      \n                      , a platform to give information and tools to physicians and people who suffer from migraine and other headaches. TJS: In the last 24\u2009months served as a consultant for AbbVie, Lundbeck, and Salvia, received royalties from UpToDate, had research support from AbbVie, American Heart Association, Flinn Foundation, Henry Jackson Foundation, National Headache Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, Pfizer, and US Department of Defense, and had stock options\/equity in Allevalux and Nocira. KMF: Managing director of MIST Research, which has received research funding from AbbVie, Allay Lamp, NYC Langone Health, Juva Health, Migraine Canada, AESARA, and Aptar. LA, FD, KHB: Employees of and own stock\/options in Pfizer.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"200"}}